A BILL 
To amend the Public Health Service Act to improve the 
diversity of participants in research on Alzheimer’s dis-
ease, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Equity in Neuroscience 
4
and Alzheimer’s Clinical Trials Act of 2021’’ or the 
5
‘‘ENACT Act of 2021’’. 
6
04:15 Jun 10, 2021
H3085
2 
•HR 3085 IH
SEC. 2. INCENTIVES, IMPROVEMENTS, AND OUTREACH TO 
1
INCREASE DIVERSITY IN ALZHEIMER’S DIS-
2
EASE RESEARCH. 
3
(a) IMPROVING ACCESS
FOR
AND OUTREACH
TO 
4
UNDERREPRESENTED POPULATIONS.— 
5
(1) EXPANDING ACCESS TO ALZHEIMER’S RE-
6
SEARCH CENTERS.— 
7
(A) IN
GENERAL.—Section 445(a)(1) of 
8
the Public Health Service Act (42 U.S.C. 285e– 
9
2(a)(1)) is amended— 
10
(i) by striking ‘‘(a)(1) The Director of 
11
the Institute may’’ and inserting the fol-
12
lowing: 
13
‘‘(a)(1) The Director of the Institute— 
14
‘‘(A) may’’; 
15
(ii) by striking ‘‘disease.’’ and insert-
16
ing ‘‘disease; and’’; and 
17
(iii) by adding at the end the fol-
18
lowing: 
19
‘‘(B) beginning January 1, 2022, shall enter 
20
into cooperative agreements and make grants to 
21
public or private nonprofit entities under this sub-
22
section for the planning, establishment, and oper-
23
ation of new such centers that are located in areas 
24
with a higher concentration of minority groups (as 
25
determined under section 444(d)(3)(D)), such as en-
26
04:15 Jun 10, 2021
H3085
3 
•HR 3085 IH
tities that are historically Black colleges and univer-
1
sities, Hispanic-serving institutions, Tribal colleges 
2
and universities, or centers of excellence for other 
3
minority populations.’’. 
4
(B) USE OF FUNDING FOR CLINICS TO OP-
5
ERATE
CLINICAL
TRIALS.—Section 445(b) of 
6
the Public Health Service Act (42 U.S.C. 285e– 
7
2(b)) is amended by adding at the end the fol-
8
lowing: 
9
‘‘(3) Federal payments made under a cooperative 
10
agreement or grant under subsection (a) from funds made 
11
available under section 2(g) of the ENACT Act of 2021 
12
shall, with respect to Alzheimer’s disease, be used in part 
13
to establish and operate diagnostic and treatment clinics 
14
designed— 
15
‘‘(A) to meet the special needs of minority and 
16
rural populations and other underserved populations; 
17
and 
18
‘‘(B) to operate clinical trials’’. 
19
(2) OUTREACH.— 
20
(A) ALZHEIMER’S
DISEASE
CENTERS.— 
21
Section 445(b) of the Public Health Service Act 
22
(42 U.S.C. 285e–2(b)), as amended by para-
23
graph (1)(B), is further amended by adding at 
24
the end the following new paragraph: 
25
04:15 Jun 10, 2021
H3085
4 
•HR 3085 IH
‘‘(4) Federal payments made under a cooperative 
1
agreement or grant under subsection (a) shall be used to 
2
establish engagement centers to carry out public outreach, 
3
education efforts, and dissemination of information for 
4
members of minority groups about clinical trial participa-
5
tion. Activities funded pursuant to the preceding sentence 
6
shall include— 
7
‘‘(A) using established mechanisms to encour-
8
age members of minority groups to participate in 
9
clinical trials on Alzheimer’s disease; 
10
‘‘(B) expanding education efforts to make mem-
11
bers of minority groups aware of ongoing clinical 
12
trials; 
13
‘‘(C) working with trial sponsors to increase the 
14
number of recruitment events for members of minor-
15
ity groups; 
16
‘‘(D) conducting outreach to national, State, 
17
and local physician professional organizations, espe-
18
cially for members of such organizations who are 
19
primary care physicians or physicians who specialize 
20
in dementia, to increase awareness of clinical re-
21
search opportunities for members of minority 
22
groups; and 
23
04:15 Jun 10, 2021
H3085
5 
•HR 3085 IH
‘‘(E) using community-based participatory re-
1
search methodologies to engage with minority popu-
2
lations.’’. 
3
(B) RESOURCE
CENTERS
FOR
MINORITY 
4
AGING RESEARCH.—Section 444(c) of the Pub-
5
lic Health Service Act (42 U.S.C. 285e–1(c)) is 
6
amended— 
7
(i) by striking ‘‘(c)’’ and inserting 
8
‘‘(c)(1)’’ ; and 
9
(ii) by adding at the end the following 
10
new paragraph: 
11
‘‘(2) The Director, acting through the Resource Cen-
12
ters for Minority Aging Research of the Institute, shall 
13
carry out public outreach, education efforts, and dissemi-
14
nation of information for members of minority groups 
15
about participation in clinical research on Alzheimer’s dis-
16
ease carried out or supported under this subpart.’’. 
17
(b) INCENTIVES TO INCREASE DIVERSITY IN ALZ-
18
HEIMER’S DISEASE RESEARCH THROUGH PRINCIPAL IN-
19
VESTIGATORS
AND
RESEARCHERS
FROM
UNDERREP-
20
RESENTED POPULATIONS.— 
21
(1) ALZHEIMER’S
CLINICAL
RESEARCH
AND 
22
TRAINING
AWARDS.—Section 445I of the Public 
23
Health Service Act (42 U.S.C. 285e–10a) is amend-
24
04:15 Jun 10, 2021
H3085
6 
•HR 3085 IH
ed by adding at the end the following new sub-
1
section: 
2
‘‘(d) ENHANCING THE PARTICIPATION OF PRINCIPAL 
3
INVESTIGATORS AND RESEARCHERS WHO ARE MEMBERS 
4
OF UNDERREPRESENTED POPULATIONS.— 
5
‘‘(1) IN GENERAL.—The Director shall enhance 
6
diversity in the conduct or support of clinical re-
7
search on Alzheimer’s disease under this subpart by 
8
encouraging the participation of individuals from 
9
groups that are underrepresented in the biomedical, 
10
clinical, behavioral, and social sciences as principal 
11
investigators of such clinical research, as researchers 
12
for such clinical research, or both. 
13
‘‘(2) TRAINING
FOR
PRINCIPAL
INVESTIGA-
14
TORS.—The Director of the Institute shall provide 
15
training for principal investigators who are members 
16
of a minority group with respect to skills for— 
17
‘‘(A) the design and conduct of clinical re-
18
search and clinical protocols; 
19
‘‘(B) applying for grants for clinical re-
20
search; and 
21
‘‘(C) such other areas as the Director de-
22
termines to be appropriate.’’. 
23
(2) SENIOR
RESEARCHER
AWARDS.—Section 
24
445B(a) of the Public Health Service Act (42 
25
04:15 Jun 10, 2021
H3085
7 
•HR 3085 IH
U.S.C. 285e–4(a)) is amended by inserting ‘‘, in-
1
cluding senior researchers who are members of a mi-
2
nority group’’ before the period at the end of the 
3
first sentence. 
4
(c) INCENTIVES TO INCREASE DIVERSITY IN ALZ-
5
HEIMER’S DISEASE RESEARCH THROUGH TRIAL SITES.— 
6
Section 444(d) of the Public Health Service Act (42 
7
U.S.C. 285e–1(d)) is amended— 
8
(1) by striking ‘‘(d)’’ and inserting ‘‘(d)(1)’’ ; 
9
and 
10
(2) by adding at the end the following new 
11
paragraphs: 
12
‘‘(2) In conducting or supporting clinical research on 
13
Alzheimer’s disease for purposes of this subpart, in addi-
14
tion to requirements otherwise imposed under this title, 
15
including under section 492B, the Director of the Institute 
16
shall increase the participation of members of minority 
17
groups in such clinical research through one or more of 
18
the activities described in paragraph (3). 
19
‘‘(3)(A) The Director of the Institute shall provide 
20
incentives for the support of clinical research on Alz-
21
heimer’s disease with clinical trial sites established in 
22
areas with a higher concentration of minority groups, in-
23
cluding rural areas if practicable. 
24
04:15 Jun 10, 2021
H3085
8 
•HR 3085 IH
‘‘(B) In determining whether to conduct or support 
1
clinical research on Alzheimer’s disease, the Director of 
2
the Institute shall encourage the conduct of clinical re-
3
search with clinical trial sites in areas described in sub-
4
paragraph (A) as a higher-level priority criterion among 
5
the criteria established to evaluate whether to conduct or 
6
support clinical research. 
7
‘‘(C) In determining the amount of funding to be pro-
8
vided for the conduct or support of such clinical research, 
9
the Director of the Institute shall provide additional fund-
10
ing for the conduct of such clinical research with clinical 
11
trial sites in areas described in subparagraph (A). 
12
‘‘(D) In determining whether an area is an area with 
13
a higher concentration of minority groups, the Director 
14
of the Institute— 
15
‘‘(i) shall consider the most recent data col-
16
lected by the Bureau of the Census; and 
17
‘‘(ii) may also consider— 
18
‘‘(I) data from the Centers for Medicare & 
19
Medicaid Services on the incidence of Alz-
20
heimer’s disease in the United States by region; 
21
and 
22
‘‘(II) such other data as the Director de-
23
termines appropriate. 
24
04:15 Jun 10, 2021
H3085
9 
•HR 3085 IH
‘‘(4) In order to facilitate the participation of mem-
1
bers of minority groups in clinical research supported 
2
under this subpart, in addition to activities described in 
3
paragraph (3), the Director of the Institute shall— 
4
‘‘(A) ensure that such clinical research uses 
5
community-based participatory research methodolo-
6
gies; and 
7
‘‘(B) encourage the use of remote health tech-
8
nologies, including telehealth, remote patient moni-
9
toring, and mobile technologies, that reduce or elimi-
10
nate barriers to participation of members of minor-
11
ity groups in such clinical research. 
12
‘‘(5)(A) Clinical research on Alzheimer’s disease con-
13
ducted or supported under this subpart shall ensure that 
14
such research includes outreach activities designed to in-
15
crease the participation of members of minority groups in 
16
such research. 
17
‘‘(B)(i) Each applicant for a grant under this subpart 
18
for clinical research on Alzheimer’s disease shall submit 
19
to the Director of the Institute in the application for such 
20
grant— 
21
‘‘(I) a budget for outreach activities to members 
22
of minority populations with respect to participation 
23
in such clinical research; and 
24
04:15 Jun 10, 2021
H3085
10 
•HR 3085 IH
‘‘(II) a description of the plan to conduct such 
1
outreach. 
2
‘‘(ii) The Director of the Institute shall encourage ap-
3
plicants for, and recipients of, grants under this subpart 
4
to conduct clinical research on Alzheimer’s disease to en-
5
gage with community-based organizations to increase par-
6
ticipation of minority populations in such research. 
7
‘‘(6) For purposes of this subpart: 
8
‘‘(A) The term ‘clinical research’ includes a 
9
clinical trial. 
10
‘‘(B) The term ‘minority group’ has the mean-
11
ing given such term by reason of section 492B(g).’’. 
12
(d) PARTICIPANT ELIGIBILITY CRITERIA.—Section 
13
445I of the Public Health Service Act (42 U.S.C. 285e– 
14
10a), as amended by subsection (b)(1), is further amended 
15
by adding at the end the following new subsection: 
16
‘‘(e) PARTICIPANT ELIGIBILITY CRITERIA.—The Di-
17
rector of the Institute shall take such actions as are nec-
18
essary to ensure that clinical research on Alzheimer’s dis-
19
ease conducted or supported under this subpart is de-
20
signed with eligibility criteria that ensure the clinical trial 
21
population reflects the diversity of the prospective patient 
22
population. Such actions may include the following: 
23
‘‘(1) EXAMINATION OF CRITERIA.— 
24
04:15 Jun 10, 2021
H3085
11 
•HR 3085 IH
‘‘(A) IN
GENERAL.—An examination of 
1
each exclusion criterion to determine if the cri-
2
terion is necessary to ensure the safety of trial 
3
participants or to achieve the study objectives. 
4
‘‘(B) MODIFICATION OF CRITERIA.—In the 
5
case of an exclusion criterion that is not nec-
6
essary to ensure the safety of trial participants 
7
or to achieve the study objectives— 
8
‘‘(i) encouraging the modification or 
9
elimination of the criterion; or 
10
‘‘(ii) encouraging tailoring the cri-
11
terion as narrowly as possible to avoid un-
12
necessary limits to the population of the 
13
clinical study. 
14
‘‘(2) REQUIREMENT
FOR
STRONG
JUSTIFICA-
15
TION FOR EXCLUSION.—A review of each exclusion 
16
criterion to ensure that populations are included in 
17
clinical trials, such as older adults, individuals with 
18
a mild form of disease, individuals at the extremes 
19
of the weight range, or children, unless there is a 
20
strong clinical or scientific justification to exclude 
21
them. 
22
‘‘(3) USE OF ADAPTIVE DESIGN.—Encouraging 
23
the use of an adaptive clinical trial design that— 
24
04:15 Jun 10, 2021
H3085
12 
•HR 3085 IH
‘‘(A) starts with a defined population 
1
where there are concerns about safety; and 
2
‘‘(B) may expand to a broader population 
3
based on initial data from the trial and external 
4
data.’’. 
5
(e) RESOURCE CENTER FOR SUCCESSFUL STRATE-
6
GIES
TO
INCREASE
PARTICIPATION
OF
UNDERREP-
7
RESENTED
IN
ALZHEIMER’S
DISEASE 
8
CLINICAL RESEARCH.—Section 444 of the Public Health 
9
Service Act (42 U.S.C. 285e–1) is amended by adding at 
10
the end the following new subsection: 
11
‘‘(e)(1) Acting through the Office of Special Popu-
12
lations and in consultation with the Division of Extra-
13
mural Activities, the Director of the Institute shall support 
14
resource information and technical assistance to grantees 
15
under section 445 (relating to Alzheimer’s disease cen-
16
ters), other grantees, and prospective grantees, designed 
17
to increase the participation of minority populations in 
18
clinical research on Alzheimer’s disease conducted or sup-
19
ported under this subpart. 
20
‘‘(2) The resource information and technical assist-
21
ance provided under paragraph (1) shall include the main-
22
tenance of a central resource library in order to collect, 
23
prepare, analyze, and disseminate information relating to 
24
strategies and best practices used by recipients of grants 
25
04:15 Jun 10, 2021
H3085
13 
•HR 3085 IH
under this subpart and other researchers in the develop-
1
ment of the clinical research designed to increase the par-
2
ticipation of minority populations in such clinical re-
3
search.’’. 
4
(f) ANNUAL REPORTS.—Section 444 of the Public 
5
Health Service Act (42 U.S.C. 285e–1), as amended by 
6
subsection (e), is further amended by adding at the end 
7
the following new subsection: 
8
‘‘(f)(1)(A) The Director of the Institute shall submit 
9
annual reports to the Congress on the impact of the 
10
amendments made to this subpart by the ENACT Act of 
11
2021. 
12
‘‘(B) The Secretary shall transmit a copy of each 
13
such report to the Advisory Council on Alzheimer’s Re-
14
search, Care, and Services established under section 2(e) 
15
of the National Alzheimer’s Project Act (Public Law 111– 
16
375). 
17
‘‘(2) In each report under paragraph (1), the Director 
18
of the Institute shall include information and data on the 
19
following matters with respect to clinical trials on Alz-
20
heimer’s disease conducted during the preceding year: 
21
‘‘(A) The number of participants who are mem-
22
bers of a minority group in such clinical trials. 
23
‘‘(B) The number of such clinical trials for 
24
which incentives under subsection (d)(3) were made 
25
04:15 Jun 10, 2021
H3085
14 
•HR 3085 IH
available, the nature of such incentives, the amount 
1
of increased funding (if any) made available for re-
2
search on Alzheimer’s disease, and the training pro-
3
vided to principal investigators who are members of 
4
a minority group and the amount of funding (if any) 
5
for such training. 
6
‘‘(C) The number of such clinical trials for 
7
which the principal investigator is a member of a mi-
8
nority group. 
9
‘‘(D) The number of such clinical trials for 
10
which a significant percentage of researchers are 
11
members of a minority group. 
12
‘‘(E) Modifications to patient eligibility criteria 
13
in clinical trial designs under section 445I(e). 
14
‘‘(F) Outreach and education efforts conducted 
15
under section 445(b)(3). 
16
‘‘(3) The Director of the Institute shall make each 
17
report under paragraph (1) available to the public, includ-
18
ing through posting on the appropriate website of the De-
19
partment of Health and Human Services.’’. 
20
(g) AUTHORIZATION OF APPROPRIATIONS.—For each 
21
of fiscal years 2022 through 2026, there is authorized to 
22
be appropriated to the Secretary of Health and Human 
23
04:15 Jun 10, 2021
H3085
15 
•HR 3085 IH
Services $60,000,000 to carry out the amendments made 
1
by this section, to remain available until expended. 
2
Æ 
04:15 Jun 10, 2021
H3085
